JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walter, M. A.
Right arrow Articles by Müller, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walter, M. A.
Right arrow Articles by Müller, B.
Journal of Nuclear Medicine Vol. 48 No. 8 1403a
© 2007 by Society of Nuclear Medicine

doi: 10.2967/jnumed.107.041731

Antithyroid Drugs and Radioiodine and the Absence of Evidence

Martin A. Walter, Jan Müller-Brand and Beat Müller

University Hospital, Basel, Switzerland

TO THE EDITOR: With interest we read the instructive review on the treatment of thyrotoxicosis by lagaru and McDougall (1). Therein, the authors stated that the outcome of radioiodine therapy with adjunctive methimazole or carbimazole would be equal to or better than that achieved when no antithyroid medication is administered. This statement is in compliance with the conclusion of most trials on the subject conducted over the last 60 y, including one of our trials cited in the review (2). Nevertheless, based on recent data the conclusion has to be refuted.

Recent findings from the first systematic review and metaanalysis on antithyroid drugs and radioiodine led us, unexpectedly, to the opposite conclusion (3). Indeed, all adjunctive antithyroid drugs given in the week before or after radioiodine therapy reduced the overall success. On the other hand, we found that concomitant antithyroid drugs reduced the postradioiodine exacerbation of hyperthyroidism and potentially decreased the morbidity and mortality of radioiodine therapy for hyperthyroidism. The major lesson by rebutting most previous studies including one of our own, however, was that even 6 decades of absent evidence still do not mean evidence of absent negative effects of antithyroid drugs on radioiodine treatment.

Every administration of antithyroid drugs in the week before or after radioiodine therapy will alter the overall outcome. Adequately powered trials are warranted to study the effects of longer discontinuation periods.

FOOTNOTES

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

References

  1. lagaru A, McDougall IR. Treatment of thyrotoxicosis. J Nucl Med. 2007;48:379–389.[Abstract/Free Full Text]
  2. Walter MA, Christ-Crain M, Schindler C, Muller-Brand J, Muller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging. 2006;33:730–737.[CrossRef][Medline]
  3. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;334:514–517.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walter, M. A.
Right arrow Articles by Müller, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walter, M. A.
Right arrow Articles by Müller, B.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE